Multiple myeloma is an incurable blood cancer. Although progress has been made in treating multiple myeloma, the five-year relative survival rate remains one of the lowest of all cancers. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next generation multiple myeloma treatments to extend the lives of patients and lead to a cure. Since its inception in 1998, the MMRF has raised more than $200 million, making it the world's leading private funder of myeloma research to deliver new treatments to patients faster. The work of the MMRF contributed to the FDA approval of four drugs for multiple myeloma in just four years - a track record unparalleled in oncology. Due to their success in myeloma, these same drugs are now being explored as potential treatments for more than 30 other cancers. As exceptional stewards of its donors’ investments, the MMRF consistently surpasses its peers in fiscal responsibility and an outstanding 90% of total budget go directly towards research and related programming. The MMRF is consistently recognized in the top 1% of all charities reviewed by evaluators like Charity Navigator. Led by Founder and CEO Kathy Giusti, a multiple myeloma patient and Harvard MBA, the MMRF is one of the most highly regarded cancer foundations in the world, well known for its innovative and results-oriented business model approach to funding cancer research.